Press Release

Distributing Agreement for Clenafin/Jublia in KoreaMay 31, 2016

Tokyo, May 31, 2016 - Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced today that Kaken and Dong-A ST Co., Ltd. (“Dong-A”, head office Dongdaemun-gu, Seoul; President and Representative Director Soo-Hyoung Kang) concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” [“Product”, (generic name: efinaconazole)] in Korea.

According to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.
Dong-A expect to obtain an approval of the Product at 2017 in Korea.

About Dong-A

  • Company name
    Dong-A ST Co., Ltd.
    Soo-Hyoung Kang
    Head Quarter
    Seoul, Republic of Korea
    KRW 40.2 billion (USD 365 million)
    KRW 567.9 billion (USD 5,162 million)

Back to list